double-labeled with 2-(4'-(2''-iodoacetamido)phenyl)aminonaphthalene-6sulfonic acid (IAANS) was greater at higher temperatures, i.e. 0.11, 0.25 and 0.66 log units at 21 , 30 and 45 C respectively. In cardiac skinned fibers at higher temperatures, Ca 2þ binding affinity (-log Ca50) was further increased for D145E (from pCa50 5.5550.01 at 15 C to 6.3450.02 at 30 C) than for WT (pCa50 5.3950.01 at 15 C to 5.9650.04 at 30 C), so that DpCa50 measured at different temperatures increased in a linear fashion. Maximal tension (P0) was markedly lower for D145E compared to WT at 30 C. These data indicate that D145É s instability dictates its impaired function within the physiological milieu. NIH-HL103840 (JRP) 2303-Pos Board B322 Non-invasive remote ischemic conditioning, repetitive brief ischemia of the arm or leg through alternating inflation and deflation of a blood-pressure cuff, has been demonstrated to produce cardioprotection in animal models and in clinical studies. Our previous study using an in vivo rat ischemia model demonstrated a decrease in maximal force per cross-sectional area (Fmax) and the rate constant of force activation (k act ) following flash photolysis of caged Ca 2þ (NP-EGTA), which correlated with a decrease in phosphorylation of troponin I (TnI) and myosin binding protein-C (MyBP-C), important regulators of muscle contraction and targets of the cAMP-dependent protein kinase (PKA) upon b-adrenergic receptor (b-AR) stimulation. Therefore, we hypothesized that remote ischemic conditioning would mitigate the decrease in mechanical function following acute ischemia by reversing ischemia-derived decreases in phosphorylation of sarcomeric proteins and/or of PKA subunits. To test this hypothesis, we examined Fmax, k act , and phosphorylation status of MyBP-C, TnT, TnI, and PKA subunits in control, ischemic and conditioned rat myocardia. Remote ischemic conditioning was simultaneously applied to experimental rats undergoing 30-min acute myocardial ischemia with LAD ligation by executing 3 cycles of 5-min inflation and deflation of a bloodpressure cuff mounted on the left hind limb. Our data show that remote ischemic conditioning significantly blunts the reduction in Fmax (72.5 5 4.9 vs 53.7 5 3.4 vs 64.9 5 2.4 mN/mm 2 ; control vs ischemic vs conditioned, n=9; P < 0.05) and in k act (24.4 5 1.9 vs 19.1 5 1.0 vs 23.1 5 1.1 s À 1; control vs ischemic vs conditioned, n=9; P < 0.05), which correlates with reversal of ischemia-derived decreases in phosphorylation of target proteins of PKA. These data suggest that remote conditioning merits additional study for its beneficial role in ischemia-induced myocardial dysfunction.
Several studies have implicated MyBP-C in the development of cardiac and recently skeletal myopathies, underlining its importance in normal sarcomeric function. Mutations in the slow skeletal isoform of MyBP-C (sMyBP-C) have been causally linked to severe and lethal forms of arthrogryposis, a family of neuromuscular diseases. Two missense mutations within MYBPC1, the gene that encodes sMyBP-C, located within the NH2-terminal M-motif (W236R) and the COOH-terminal immunoglobulin (Ig) C8 domain (Y856H) have been linked to the development of distal arthrogryposis type-1 (DA-1), a skeletal muscle disorder characterized by contractures of the distal limbs. Here we explore the molecular defects that underlie the development of DA-1. using a combination of in vitro binding and motility assays, we show that the presence of the W236R mutation abolishes the ability of the NH2-terminus to modulate the formation of actomyosin cross-bridges, while the presence of the Y856H mutation inhibits Ig domains C8-C10 from interacting with native myosin filaments. Our findings therefore suggest that distinct mechanisms may underlie the pathogenesis of DA-1 myopathy depending on the location of the individual mutation within sMyBP-C. We are currently examining the effects of overexpressing mutant sMyBP-C proteins carrying either the W236R or the Y856H mutation in a sMyBP-C-null background, via in vivo gene transfer. In summary, our studies are the first to provide a mechanistic interpretation of the pathogenesis of distal arthrogryposis.
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How Muscle Exploits the Steady State to Regulate Contraction Henry G. Zot 1 , Javier E. Hasbun 1 , Nguyen Van Minh 2 . 1 University of West Georgia, Carrollton, GA, USA, 2 Columbus State University, Columbus, GA, USA. Activation of muscle requires myosin binding. The active state of muscle is stabilized by high affinity rigor bonds at equilibrium but, the steady-state catalytic cycle of myosin ATPase decreases the lifetime of the myosin interaction by several orders of magnitude. Low myosin affinity could be a justification for including Ca 2þ binding states in a model of activation. Our work supports a simple model for steady state activation, namely, the regulatory protein tropomyosin (Tm) exists in just two states, ground (C) and excited (M), separated by an energy barrier which can be overcome by interaction with myosin. The elongated shape of Tm allows for multiple potential myosin binding partners (U i ). During its strong binding phase of the catalytic cycle, any one myosin (U 1 ) combines with C to form M by an equilibrium pathway. At time, t=0, M probability, P M =1. Although U 1 most likely decays by a non-equilibrium rate (i.e., ATP binding), the lifetime of P M is constant. For t>0, before M decays to C, interaction with U i in the strong binding phase can restore P M =1. We show that an analytical function (M function) is fully derived from the combination of equilibrium and steady state pathways and the additional opportunities (second chances) to restore P M =1 depend on the rate at which U i transitions into the strong binding phase. When Ca 2þ is introduced as a mass action regulator of the U or C supply, the M function takes the general form of the Hill equation, which is widely employed for fitting the steady state response of muscle to Ca 2þ . We show by simulations that stochastic events predicted by a second chance mechanism are consistent with solutions to the M function. Our results justify kinetic experiments that focus specifically on M.
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Troponin I Serine 150 Phosphorylation Inhibits pH-Induced Troponin Calcium Desensitization Benjamin R. Nixon, Shane D. Walton, Sean C. Little, Jonathan P. Davis, Brandon J. Biesiadecki. The Ohio State University, Columbus, OH, USA. A hallmark of cardiac ischemia is decreased intracellular pH which can affect a number of cellular processes. Such an acidic environment alters cardiac troponin (Tn) myofilament regulation to decrease the Ca 2þ sensitivity of force production. Tn also undergoes cardiac ischemic-induced AMPK troponin I (TnI) Ser-150 phosphorylation. We recently characterized the effect of TnI Ser-150 phosphorylation demonstrating it to increase myofilament Ca 2þ sensitivity and blunt TnI PKA phosphorylation-induced desensitization. The effect of an acidic environment on Tn myofilament regulation in the presence of the ischemic-induced TnI Ser-150 phosphorylation is unknown. In this study we investigate the effect of pH on myofilament regulation in the presence of TnI Ser-150 phosphorylation. Myofilament regulation was determined by measuring troponin C Ca 2þ binding properties at normal and acidic pH. Results demonstrate acidic pH decreases steady-state Ca 2þ binding to troponin C in thin filaments reconstituted with either WT or Ser-150 pseudo-phosphorylated TnI (Tn S150D) such that Tn S150D Ca 2þ sensitivity at pH 6.5 is similar to WT at pH 7. Furthermore, while Tn S150D slowed Ca 2þ dissociation compared to Tn WT at pH 7.0, decreasing the pH to 6.5 did not further alter isolated Tn S150D Ca 2þ dissociation indicating a lack of pH to modulate Tn Ca 2þ dissociation kinetics. Thin filament dissociation kinetics are ongoing. We conclude that TnI Ser-150 phosphorylation imparts resistance to acidic pH induced myofilament Ca 2þ desensitization similar to that present during ischemia without alteration of Tn Ca 2þ dissociation. Future investigations are aimed at examining the effect of TnI Ser-150 phosphorylation in the presence of TnI Ser-23/24 phosphorylation at low pH.
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Phosphate Enhances Regulated Thin Filament Velocity at Acidic pH in the Motility Assay Thomas J. Longyear 1 , Matthew A. Turner 1 , Joseph Lopez 2 , Jonathan P. Davis 2 , Edward P. Debold 1 . 1 University of Massachusetts, Amherst, MA, USA, 2 The Ohio State University, Columbus, OH, USA. Elevated levels of inorganic phosphate (P i ) and hydrogen ions (H þ ) are putative agents of muscle fatigue. However, the molecular mechanisms underlying their inhibitory action on the contractile proteins remains unclear. To gain mechanistic insight into the effects of these ions on the myofilament function, we studied their impact on the velocity-pCa relationship in an in vitro motility assay. In this assay, actin filaments reconstituted with fast skeletal troponin (Tn) and tropomyosin (Tm) moved on a coverslip surface coated with skeletal myosin. At saturating Ca 2þ (pCa5), decreasing the pH from 7.4 to 6.8 and 450a Tuesday, February 5, 2013 6.5 significantly (p<0.05) reduced filament velocity by 47 and 95%, respectively. In addition, filament velocity was depressed at any given submaximal Ca 2þ level with the effect significantly more pronounced at pH 6.5 vs 6.8. However, the pCa 50 increased significantly (p<0.05) when the pH was reduced from 7.4 to 6.8 (6.7650.07 vs. 7.6250.14) but was not significantly affected at pH 6.5 (6.6250.82). This suggests a complex relationship between pH and Ca 2þsensitivity. The addition of P i had no effect on filament velocity at pH 7.4 but significantly reversed the acidosis-induced depression in velocity at both pH 6.8 and 6.5, at every level of Ca 2þ from pCa 7.0 to pCa 5.0. The addition of P i also increased the pCa 50 at pH 6.5 from 6.6250.82 to 7.7450.20. The effects of these ions on regulated thin filament velocity are significantly more pronounced than those observed with unregulated actin filaments (Debold et al., 2011) ; therefore, we are now attempting to identify the structural regions responsible by assessing the functional impact of structural alterations to key regions of Tn. We have used stopped-flow fluorescence to measure the acceleration of dissociation of hydrolysis products, Pi and deoxymantADP (mdADP), from myosinS1-mdADP-Pi and myosinS1-mdADP by native cardiac thin filaments (TF) at near physiological ionic strength (0.1M KAc). Although the rate constants of the product dissociation steps cannot be measured at this ionic strength, there is a linear dependence of the k obs of product (Pr = mdADP or mdADP-Pi) dissociation (TF þ M-Pr 4 TF-M-Pr / TF-M þ Pr) on [TF], which can be used to determine the dependence of the apparent second order rate constant upon the ligands calcium and rigor myosin. The second order rate constant of the dependence of the k obs of Pi dissociation from myosinS1-mdADP-Pi on thin filament (actin subunit) concentration is: 2x10 3 M À1 s À1 (no rigor myosin, pCa>8), 5.9x10 4 M À1 s À1 (rigor myosin, pCa>8), 1.3x10 5 M À1 s À1 (no rigor myosin, pCa<4), and 1.8x10 5 M À1 s À1 (rigor myosin, pCa<4). The second order rate constant of the dependence of the k obs of mdADP dissociation from myosinS1-mADP on thin filament concentration is: 4.2x10 4 M À1 s À1 (no rigor myosin, pCa>8), 2.3x10 5 M À1 s À1 (rigor myosin, pCa>8), 6.2x10 5 M À1 s À1 (no rigor myosin, pCa<4), and 1.2x10 6 M À1 s À1 (rigor myosin, pCa<4). Thus, neither calcium nor rigor myosin is sufficient to maximally activate thin filament acceleration of product dissociation on its own. Full activation requires both calcium and rigor myosin to be bound to the thin filament. These results are (i) similar to data previously obtained at low ionic strength; (ii) inconsistent with models which predict that rigor myosin fully activates the thin filament and (iii) support a mechanism of thin filament regulation in which the principal regulated step of the hydrolysis cycle is phosphate dissociation from actomyosin-ADP-Pi. Increases in muscle nitric-oxide (NO) production can be buffered by reaction with intracellular glutathione, forming S-nitrosoglutathione (GSNO). GSNO has been shown to S-nitrosylate Cys thiols of cardiac contractile proteins in vivo and in vitro, but effects on maximal force, thin-filament Ca 2þ sensitivity and actomyosin ATPase activity are unknown. Here, we analyzed the targets of S-nitrosylation in mouse cardiac contractile proteins, and examined the effects of these modifications on function in myocytes and skinned cardiac myofibrils. S-Nitrosylation and denitrosylation were detected using resin-assisted capture (SNO-RAC) and targets for S-nitrosylation were identified by quantitative LC-MS/MS. Isolated cardiomyocytes treated with S-nitrosocysteine (CysNO, 500mM, 10min) showed an increase in total protein-SNO, followed by progressive denitrosylation (30-60min with CysNO). At 10min, CysNO dose-dependently increased S-nitrosylation of specific Cys thiols in myosin heavy chain, actin, TnC, TnI, myosin-binding protein C and other muscle proteins. Myofibril thin-filament Ca 2þ sensitivity decreased (P<0.05) after in-vitro treatment with pharmacological GSNO concentrations (1, 10, 100 mM), but maximum force did not change (P>0.05). Loss of Ca 2þ sensitivity was partially reversed by the denitrosation agent, ascorbate. Relaxation kinetics of skinned fibers, as measured by flash photolysis, were also significantly reduced by100mM GSNO (k1,15.33 to 11.68/s; k2 2.33 to 0.87/s; fit to double exponential). Maximal myofibrillar ATPase activity (pCa 5.0) was also dosedependently inhibited (8, 15, 30%) by 50, 100 and 500mM GSNO, an effect that was reversed by ascorbate. The findings suggest that S-nitrosylation of regulatory Cys thiol(s) can reversibly modulate cardiac muscle contraction and may be able to protect the heart by reducing myosin ATPase demand without affecting the maximal force of contraction.
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2309-Pos Board B328 S-Nitrosylation Decreases Ca 2D Sensitivity and Actomyosin ATPase Activity of Contractile Proteins in Cardiac Myofibrils
2310-Pos Board B329 A Novel Role of Caldesmon during Smooth Muscle Relaxation
Chih-Lueh Albert Wang, Toshio Kitazawa. Boston Biomedical Research Institute, Watertown, MA, USA. The effect of h-caldesmon (h-CaD) on smooth muscle contractility was examined by force measurements on tissues isolated from wild-type (WT) and h-CaD-null (KO) mice. Both aorta and tail arteries from KO mice relaxed more slowly than that from WT animals. The force decay of beta-escinpermeabilized, kinase-inhibited tissues under pCa>9 was best fitted with a two-exponential process. We found that the apparently slower relaxation for the KO samples was not due to lower rate constants, but rather, was because of increased amplitude of the slower component of the decay. To search for an explanation for the observed relaxation kinetics, we drew some lessons from the work done on striated muscles. Muscle relaxation involves two major events: crossbridge detachment and change of the thin filament from active to inactive state. The latter occurs first, corresponding to the initial lag phase, followed by the rapid force decay, the crossbridge detachment. In smooth muscle, the lag phase is ascribed to myosin dephosphorylation, but it may also include the filament state change, i.e., CaD-tropomyosin moving to a position on actin filaments that hinders myosin binding. This ''off-position'' is under strain, because the dephosphorylated crossbridges are still attached. Assuming that there are two possible positions for CaD-tropomyosin to occupy, one displacing the bound myosin more promptly than the other, the crossbridge would detach at two different rates, resulting in the observed biphasic decay. Our data then suggest that when h-CaD is absent, fewer tropomyosin molecules are at the blocking position. Thus, the return of smooth muscle tropomyosin to the proper inhibitory position upon relaxation needs help from h-CaD. In striated muscle the movement of tropomyosin was shown to be facilitated by troponin subunits. CaD may play a troponin-like role in smooth muscle both structurally and functionally. It is generally accepted that dephosphorylation of regulatory light chain (RLC) induces the interactions between the two heads of smooth muscle myosin (Sm) and between the head and the tail, thus inhibiting the motor activity, and phosphorylation of RLC interrupts above interactions, thus reversing the inhibition and stimulating the motor activity to maximal value. Thus it is predicted that Sm subfragment-1 (S1) containing only one head without the tail is fully active. However, no solid evident so far supports this prediction, although early studies showed that S1 produced by limited protease treatment is partially active. Here we produced a number of Sm truncations with various length of the tail. The stability of double-headed structure of Sm is dependent on the length of the coiled-coil tail. The Sm truncations with coiled-coil longer than 214 amino acids form stable double-headed structure (stable HMM), those with coiledcoil shorter than 179 amino acids form unstable double headed structure (unstable HMM), and that without coiled-coil, i.e. S1, is completely single-headed. Phosphorylation of RLC regulates the motor activity of stable HMM completely, regulates that of unstable HMM partially, and does not regulate that of S1. Unexpectedly, the actin-activated ATPase activity of S1, either unphosphorylated or phosphorylated, is higher than that of unphosphorylated stable HMM but less than 10% of that of phosphorylated stable HMM. The actinactivated ATPase activities of unphosphorylated Sm truncations increase with the shortening of the coiled-coil tail, and that of phosphorylated Sm truncations decrease with the shortening of the coiled-coil tail. These results indicate that the stable double-headed structure is critical not only for the inhibited
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